Curis (CRIS) vs Scinai Immunotherapeutics (SCNI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Curis is the larger company by market cap ($1.7 million vs $1.6 million), about 1.1 times the size. On valuation, Scinai Immunotherapeutics trades at a lower trailing P/E (0.0x vs 0.5x for Curis).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRIS | SCNI |
|---|---|---|
| Share price | $0.7094 | $1.21 |
| Market cap | $1.72M | $1.64M |
| 1-day change | -3.69% | +7.08% |
| P/E ratio (TTM) | 0.54 | 0.04 |
| EPS (TTM) | $1.32 | $28.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $33.60 | $15.65 |
| 52-week low | $0.61 | $1.06 |
| Distance from 52-week high | -97.89% | -92.27% |
| Analyst consensus | none | — |
| Avg. price target upside | +5914.94% | — |
| Average volume | 199.15K | 1.10M |
| Shares outstanding | 2.43M | 1.35M |
| Employees | 20 | 45 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Curis trades at a higher earnings multiple (0.5x vs 0.0x trailing P/E).
About Curis
CRIS stock →Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma.
Healthcare · Biotechnology · 20 employees
About Scinai Immunotherapeutics
SCNI stock →Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis.
Healthcare · Biotechnology · 45 employees
CRIS vs SCNI FAQ
Which is bigger, Curis or Scinai Immunotherapeutics?
Curis (CRIS) is larger, with a market capitalization of $1.72M compared with $1.64M for Scinai Immunotherapeutics (SCNI).
Which has the lower P/E ratio, CRIS or SCNI?
SCNI has the lower trailing P/E at 0.0, versus 0.5 for CRIS. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Curis and Scinai Immunotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.